Evaluating the effect of Atomoxetine and Oxybutynin combination on the number of apnea in obstructive sleep apnea patients

Tehran University of Medical Sciences0 个研究点目标入组 18 人开始时间: 待定最近更新: 2022年6月27日

适应症

试验速览

暂无简介。

•established OSA diagnosis in the past medical history with AHI more than 20 in the last polysomnography(if accessible)
•age between 21 and 65 years old
•noncompliant for CPAP or BiPAP
•not indicated for surgical treatment, according to the sleep specialist. or the situation that the patient doesn't tend to surgical treatment

•the existence of any other disorders(except controlled HTN, Hyperlipidemia and Diabetes)
•the consumption of any drug resulting in changes in ventilation physiology, sleep/awake cycle and the muscles; such as methocarbamol, tramadol, TCAs, SSRIs, SNRIs, ventilation stimulants and depressants, hypnotics, CNS stimulants, central sleep apnea, and etc.
•Claustrophobia
•Inability for being in supine position
•Allergy to any of lidocaine, atomoxetine, oxybutynin, vitamin C
•the existence of any underlying heart diseases such as arrhythmias
•the consumption of psychiatric drugs such as atomoxetine or any other drug that is prescribed for medical care and could not be withdrawn while the experiment night.
•for women: pregnancy
•the history of seizure, panic disorder, hyperventilation syndrome, ADHD, ASD
•Any disease that exacerbates by antimuscarinic drugs such as urinary retention, BPH, severe ulcerative colitis, glaucoma, myasthenia gravis

发起方